Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Ratio (2019 - 2025)

Historic Equity Ratio for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 1.94.

  • BridgeBio Pharma's Equity Ratio fell 563.26% to 1.94 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.94, marking a year-over-year decrease of 563.26%. This contributed to the annual value of 1.6 for FY2024, which is 3558.07% up from last year.
  • BridgeBio Pharma's Equity Ratio amounted to 1.94 in Q3 2025, which was down 563.26% from 1.66 recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Equity Ratio high stood at 0.36 for Q1 2021, and its period low was 2.68 during Q2 2023.
  • For the 5-year period, BridgeBio Pharma's Equity Ratio averaged around 1.53, with its median value being 1.6 (2024).
  • In the last 5 years, BridgeBio Pharma's Equity Ratio tumbled by 66684.56% in 2021 and then surged by 4918.83% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Equity Ratio stood at 0.86 in 2021, then plummeted by 133.12% to 2.0 in 2022, then fell by 24.2% to 2.48 in 2023, then surged by 35.58% to 1.6 in 2024, then dropped by 21.28% to 1.94 in 2025.
  • Its Equity Ratio stands at 1.94 for Q3 2025, versus 1.66 for Q2 2025 and 1.87 for Q1 2025.